Cure8 research brief
Personalizing adalimumab dosing could reduce underexposure, treatment failure, and immunogenicity for people with IBD. Validated popPK models are a key step toward reliable model-informed precision dosing in clinical practice.
Adult IBD patients (especially those on adalimumab), clinicians who manage biologic dosing or therapeutic drug monitoring, and researchers working on pharmacokinetics or MIPD.
This is a retrospective external validation (abstract-level) comparing model predictions against observed adalimumab concentrations using goodness-of-fit plots, prediction-corrected visual predictive checks, residual analysis, and statistical metrics (AIC, bias/precision measures).
Two models (Berends and Vande Casteele) performed best across most metrics, though both tended to overestimate population clearance. How this might affect care The authors conclude these two models may be suitable starting points for clinical MIPD strategies to optimize adalimumab dosing, but they note broader validation in other populations is still needed.
Sources and limits The summary is grounded in the article abstract and validation-study methods reported on PubMed; Cure8 did not review the full paper beyond the provided abstract.
This classification and note are based on the article abstract (external validation study) from PubMed. The study is retrospective and limited to a single tertiary-centre cohort; authors recommend further validation in other populations before broad clinical adoption.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Ethics approval: The study was approved by the Clinical Research Ethics Committee of Autonomous Community of Aragon (CEICA) with the following registration number: EOM24/034. The procedures established in this research are designed following the principles of good clinical practice and the declaration of Helsinki. Informed consent: All participants provided written informed consent before enrollment in the study. Competing interests: The authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Reactive TDM can help determine why a child with Crohn's disease is losing response to adalimumab and guide whether to escalate dose or switch biologics, which affects short-term management decisions.
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
